Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Sci Adv ; 4(11): eaat9365, 2018 11.
Article in English | MEDLINE | ID: mdl-30498778

ABSTRACT

We engineered a microneedle patch integrated with cardiac stromal cells (MN-CSCs) for therapeutic heart regeneration after acute myocardial infarction (MI). To perform cell-based heart regeneration, cells are currently delivered to the heart via direct muscle injection, intravascular infusion, or transplantation of epicardial patches. The first two approaches suffer from poor cell retention, while epicardial patches integrate slowly with host myocardium. Here, we used polymeric MNs to create "channels" between host myocardium and therapeutic CSCs. These channels allow regenerative factors secreted by CSCs to be released into the injured myocardium to promote heart repair. In the rat MI model study, the application of the MN-CSC patch effectively augmented cardiac functions and enhanced angiomyogenesis. In the porcine MI model study, MN-CSC patch application was nontoxic and resulted in cardiac function protection. The MN system represents an innovative approach delivering therapeutic cells for heart regeneration.


Subject(s)
Myocardial Infarction/therapy , Myocytes, Cardiac/cytology , Regeneration , Stromal Cells/cytology , Stromal Cells/transplantation , Tissue Engineering/instrumentation , Animals , Cells, Cultured , Microtechnology , Needles , Rats , Rats, Inbred WKY , Swine
2.
ACS Appl Mater Interfaces ; 10(39): 33088-33096, 2018 Oct 03.
Article in English | MEDLINE | ID: mdl-30188113

ABSTRACT

Cardiac stem cell (CSC) therapy has shown preclinical and clinical evidence for ischemic heart repair but is limited by low cellular engraftment and survival after transplantation. Previous versions of the cardiac patch strategy improve stem cell engraftment and encourage repair of cardiac tissue. However, cardiac patches that can enhance cardiomyogenesis and angiogenesis at the injured site remain elusive. Therapies that target cardiomyocyte proliferation and new blood vessel formation hold great potential for the protection against acute myocardial infarction (MI). Here, we report a new strategy for creating a vascularized cardiac patch in a facile and modular fashion by leveraging microfluidic hydrodynamic focusing to construct the biomimetic microvessels (BMVs) that include human umbilical vein endothelial cells (HUVECs) lining the luminal surface and then encapsulating the BMVs in a fibrin gel spiked with human CSCs. We show that the endothelialized BMVs mimicked the natural architecture and function of capillaries and that the resultant vascularized cardiac patch (BMV-CSC patch) exhibited equivalent release of paracrine factors compared to those of coculture of genuine human CSCs and HUVECs after 7 days of in vitro culture. In a rat model of acute MI, the BMV-CSC patch therapy induced profound mitotic activities of cardiomyocytes in the peri-infarct region 4 weeks post-treatment. A significant increase in myocardial capillary density was noted in the infarcted hearts that received BMV-CSC patch treatment compared to the infarcted hearts treated with conventional CSC patches. The striking therapeutic benefits and the fast and facile fabrication of the BMV-CSC patch make it promising for practical applications. Our findings suggest that the BMV-CSC patch strategy may open up new possibilities for the treatment of ischemic heart injury.


Subject(s)
Myocardial Infarction/therapy , Myocardium/cytology , Myocytes, Cardiac/cytology , Neovascularization, Physiologic/physiology , Stem Cells/cytology , Animals , Cells, Cultured , Female , Human Umbilical Vein Endothelial Cells , Humans , Microfluidic Analytical Techniques , Myocytes, Cardiac/physiology , Rats , Rats, Nude , Stem Cells/physiology
3.
Theranostics ; 8(7): 1869-1878, 2018.
Article in English | MEDLINE | ID: mdl-29556361

ABSTRACT

Rationale: Cardiac stem cell-derived exosomes have been demonstrated to promote cardiac regeneration following myocardial infarction in preclinical studies. Recent studies have used intramyocardial injection in order to concentrate exosomes in the infarct. Though effective in a research setting, this method is not clinically appealing due to its invasive nature. We propose the use of a targeting peptide, cardiac homing peptide (CHP), to target intravenously-infused exosomes to the infarcted heart. Methods: Exosomes were conjugated with CHP through a DOPE-NHS linker. Ex vivo targeting was analyzed by incubating organ sections with the CHP exosomes and analyzing with fluorescence microscopy. In vitro assays were performed on neonatal rat cardiomyocytes and H9C2 cells. For the animal study, we utilized an ischemia/reperfusion rat model. Animals were treated with either saline, scramble peptide exosomes, or CHP exosomes 24 h after surgery. Echocardiography was performed 4 h after surgery and 21 d after surgery. At 21 d, animals were sacrificed, and organs were collected for analysis. Results: By conjugating the exosomes with CHP, we demonstrate increased retention of the exosomes within heart sections ex vivo and in vitro with neonatal rat cardiomyocytes. In vitro studies showed improved viability, reduced apoptosis and increased exosome uptake when using CHP-XOs. Using an animal model of ischemia/reperfusion injury, we measured the heart function, infarct size, cellular proliferation, and angiogenesis, with improved outcomes with the CHP exosomes. Conclusions: Our results demonstrate a novel method for increasing delivery of for treatment of myocardial infarction. By targeting exosomes to the infarcted heart, there was a significant improvement in outcomes with reduced fibrosis and scar size, and increased cellular proliferation and angiogenesis.


Subject(s)
Biological Products/administration & dosage , Biological Therapy/methods , Exosomes , Molecular Targeted Therapy/methods , Myocardial Infarction/therapy , Peptides/administration & dosage , Administration, Intravenous , Animals , Biological Products/pharmacokinetics , Cell Survival , Disease Models, Animal , Echocardiography , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/physiology , Peptides/pharmacokinetics , Rats , Treatment Outcome
4.
J Cell Mol Med ; 21(8): 1503-1512, 2017 08.
Article in English | MEDLINE | ID: mdl-28296006

ABSTRACT

Cardiosphere-derived cells (CDCs) have been shown to reduce scar size and increase viable myocardium in human patients with mild/moderate myocardial infarction. Studies in rodent models suggest that CDC therapy may confer therapeutic benefits in patients with non-ischaemic dilated cardiomyopathy (DCM). We sought to determine the safety and efficacy of allogeneic CDC in a large animal (canine) model of spontaneous DCM. Canine CDCs (cCDCs) were grown from a donor dog heart. Similar to human CDCs, cCDCs express CD105 and are slightly positive for c-kit and CD90. Thirty million of allogeneic cCDCs was infused into the coronary vessels of Doberman pinscher dogs with spontaneous DCM. Adverse events were closely monitored, and cardiac functions were measured by echocardiography. No adverse events occurred during and after cell infusion. Histology on dog hearts (after natural death) revealed no sign of immune rejection from the transplanted cells.


Subject(s)
Cardiomyopathy, Dilated/therapy , Coronary Vessels/cytology , Spheroids, Cellular/cytology , Stem Cell Transplantation , Stem Cells/cytology , Animals , Biomarkers/metabolism , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/immunology , Cardiomyopathy, Dilated/pathology , Coronary Vessels/immunology , Dogs , Echocardiography , Endoglin/genetics , Endoglin/immunology , Female , Gene Expression , Humans , Male , Myocardium/immunology , Myocardium/pathology , Proto-Oncogene Proteins c-kit/genetics , Proto-Oncogene Proteins c-kit/immunology , Spheroids, Cellular/immunology , Spheroids, Cellular/transplantation , Stem Cells/immunology , Thy-1 Antigens/genetics , Thy-1 Antigens/immunology , Transplantation, Homologous
5.
Nat Commun ; 8: 13724, 2017 01 03.
Article in English | MEDLINE | ID: mdl-28045024

ABSTRACT

Stem cell therapy represents a promising strategy in regenerative medicine. However, cells need to be carefully preserved and processed before usage. In addition, cell transplantation carries immunogenicity and/or tumourigenicity risks. Mounting lines of evidence indicate that stem cells exert their beneficial effects mainly through secretion (of regenerative factors) and membrane-based cell-cell interaction with the injured cells. Here, we fabricate a synthetic cell-mimicking microparticle (CMMP) that recapitulates stem cell functions in tissue repair. CMMPs carry similar secreted proteins and membranes as genuine cardiac stem cells do. In a mouse model of myocardial infarction, injection of CMMPs leads to the preservation of viable myocardium and augmentation of cardiac functions similar to cardiac stem cell therapy. CMMPs (derived from human cells) do not stimulate T-cell infiltration in immuno-competent mice. In conclusion, CMMPs act as 'synthetic stem cells' which mimic the paracrine and biointerfacing activities of natural stem cells in therapeutic cardiac regeneration.


Subject(s)
Biomimetic Materials/pharmacology , Cell Membrane/metabolism , Cell-Derived Microparticles/metabolism , Culture Media, Conditioned/chemistry , Myocardial Infarction/therapy , Stem Cells/metabolism , Animals , Biomimetic Materials/chemistry , Biomimetic Materials/metabolism , Cell Fractionation , Cell Membrane/chemistry , Cell Membrane/transplantation , Cell-Derived Microparticles/chemistry , Cell-Derived Microparticles/transplantation , Culture Media, Conditioned/isolation & purification , Disease Models, Animal , Gene Expression , Hepatocyte Growth Factor/genetics , Hepatocyte Growth Factor/metabolism , Humans , Injections, Intralesional , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Intercellular Signaling Peptides and Proteins/pharmacology , Male , Mice , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardium/metabolism , Myocardium/pathology , Paracrine Communication , Recovery of Function/drug effects , Stem Cells/cytology , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
6.
Tissue Eng Part C Methods ; 23(3): 146-155, 2017 03.
Article in English | MEDLINE | ID: mdl-28068869

ABSTRACT

Layering a regenerative polymer scaffold on the surface of the heart, termed as a cardiac patch, has been proven to be effective in preserving cardiac function after myocardial infarction (MI). However, the placement of such a patch on the heart usually needs open-chest surgery, which is traumatic, therefore prevents the translation of this strategy into the clinic. We sought to device a way to apply a cardiac patch by spray painting in situ polymerizable biomaterials onto the heart with a minimally invasive procedure. To prove the concept, we used platelet fibrin gel as the "paint" material in a mouse model of MI. The use of the spraying system allowed for placement of a uniform cardiac patch on the heart in a mini-invasive manner without the need for sutures or glue. The spray treatment promoted cardiac repair and attenuated cardiac dysfunction after MI.


Subject(s)
Blood Platelets/metabolism , Fibrin/metabolism , Heart/physiology , Myocardial Infarction/therapy , Myocytes, Cardiac/cytology , Regeneration/physiology , Animals , Biocompatible Materials/chemistry , Male , Mice , Myocardial Infarction/pathology , Paintings , Rats , Rats, Sprague-Dawley
7.
Stem Cells Transl Med ; 5(6): 793-803, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27112177

ABSTRACT

UNLABELLED: Stem cells and biomaterials have been studied for therapeutic cardiac repair. Previous studies have shown the beneficial effects of platelet fibrin gel and cardiac stem cells when cotransplanted into rodent hearts with myocardial infarction (MI). We hypothesized that matrix metalloproteinases (MMPs) play an important role in such protection. Thus, the present study is designed to elucidate the effects of MMP inhibition on the therapeutic benefits of intramyocardial injection of platelet fibrin gel spiked with cardiac stem cells (cell-gel) in a rat model of acute MI. In vitro, broad-spectrum MMP inhibitor GM6001 undermines cell spreading and cardiomyocyte contraction. In a syngeneic rat model of myocardial infarction, MMP inhibition blunted the recruitment of endogenous cardiovascular cells into the injected biomaterials, therefore hindering de novo angiogenesis and cardiomyogenesis. Echocardiography and histology 3 weeks after treatment revealed that metalloproteinase inhibition diminished the functional and structural benefits of cell-gel in treating MI. Reduction of host angiogenesis, cardiomyocyte cycling, and MMP-2 activities was evident in animals treated with GM6001. Our findings suggest that MMPs play a critical role in the therapeutic benefits of platelet fibrin gel spiked with cardiac stem cells for treating MI. SIGNIFICANCE: In this study, the effects of matrix metalloproteinase inhibition on the performance of platelet gel spiked with cardiac stem cells (cell-gel) for heart regeneration are explored. The results demonstrate that matrix metalloproteinases are required for cell-gel to exert its benefits in cardiac repair. Inhibition of matrix metalloproteinases reduces cell engraftment, host angiogenesis, and recruitment of endogenous cardiovascular cells in rats with heart attack.


Subject(s)
Matrix Metalloproteinases/metabolism , Myocardial Infarction/therapy , Myocytes, Cardiac/metabolism , Stem Cell Transplantation , Animals , Blood Platelets/metabolism , Dipeptides/administration & dosage , Disease Models, Animal , Echocardiography , Fibrin/administration & dosage , Humans , Matrix Metalloproteinase Inhibitors/administration & dosage , Myocardial Infarction/enzymology , Myocardial Infarction/pathology , Myocytes, Cardiac/cytology , Myocytes, Cardiac/drug effects , Rats , Regeneration/drug effects
8.
PLoS One ; 10(11): e0143221, 2015.
Article in English | MEDLINE | ID: mdl-26599500

ABSTRACT

AIMS: The coronary artery ligation model in rodents mimics human myocardial infarction (MI). Normally mechanical ventilation and prolonged anesthesia period are needed. Recently, a method has been developed to create MI by popping-out the heart (without ventilation) followed by immediate suture ligation. Mortality is high due to the time-consuming suture ligation process while the heart is exposed. We sought to improve this method and reduce mortality by rapid coronary ligation using a surgical clip instead of a suture. METHODS AND RESULTS: Mice were randomized into 3 groups: clip MI (CMI), suture MI (SMI), or sham (SHAM). In all groups, heart was manually exposed without intubation through a small incision on the chest wall. Unlike the conventional SMI method, mice in the CMI group received a metal clip on left anterior descending artery (LAD), quickly dispensed by an AutoSuture Surgiclip™. The CMI method took only 1/3 of ligation time of the standard SMI method and improved post-MI survival rate. TTC staining and Masson's trichrome staining revealed a similar degree of infarct size in the SMI and CMI groups. Echocardiograph confirmed that both SMI and CMI groups had a similar reduction of ejection fraction and fraction shortening over the time. Histological analysis showed that the numbers of CD68+ macrophages and apoptotic cells (TUNEL-positive) are indistinguishable between the two groups. CONCLUSION: This new method, taking only less than 3 minutes to complete, represents an efficient myocardial infarction model in rodents.


Subject(s)
Coronary Vessels/surgery , Disease Models, Animal , Ligation , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Surgical Instruments , Animals , Mice , Myocardial Infarction/etiology , Myocardial Infarction/mortality , Suture Techniques , Vascular Surgical Procedures
9.
J Vis Exp ; (98)2015 Apr 09.
Article in English | MEDLINE | ID: mdl-25938862

ABSTRACT

Cell culture has become increasingly important in cardiac research, but due to the limited proliferation of cardiomyocytes, culturing cardiomyocytes is difficult and time consuming. The most commonly used cells are neonatal rat cardiomyocytes (NRCMs), which require isolation every time cells are needed. The birth of the rats can be unpredictable. Cryopreservation is proposed to allow for cells to be stored until needed, yet freezing/thawing methods for primary cardiomyocytes are challenging due to the sensitivity of the cells. Using the proper cryoprotectant, dimethyl sulfoxide (DMSO), cryopreservation was achieved. By slowly extracting the DMSO while thawing the cells, cultures were obtained with viable NRCMs. NRCM phenotype was verified using immunocytochemistry staining for α-sarcomeric actinin. In addition, cells also showed spontaneous contraction after several days in culture. Cell viability after thawing was acceptable at 40-60%. In spite of this, the methods outlined allow one to easily cryopreserve and thaw NRCMs. This gives researchers a greater amount of flexibility in planning experiments as well as reducing the use of animals.


Subject(s)
Cryopreservation/methods , Myocytes, Cardiac/cytology , Actinin/analysis , Actinin/metabolism , Animals , Animals, Newborn , Cell Culture Techniques , Cell Separation/methods , Cell Survival/physiology , Cryoprotective Agents/chemistry , Dimethyl Sulfoxide/chemistry , Freezing , Myocytes, Cardiac/metabolism , Rats , Sarcomeres/chemistry , Sarcomeres/metabolism
10.
J Cell Mol Med ; 19(8): 1805-13, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25854418

ABSTRACT

The regenerative potential of cardiosphere-derived cells (CDCs) for ischaemic heart disease has been demonstrated in mice, rats, pigs and a recently completed clinical trial. The regenerative potential of CDCs from dog hearts has yet to be tested. Here, we show that canine CDCs can be produced from adult dog hearts. These cells display similar phenotypes in comparison to previously studied CDCs derived from rodents and human beings. Canine CDCs can differentiate into cardiomyocytes, smooth muscle cells and endothelial cells in vitro. In addition, conditioned media from canine CDCs promote angiogenesis but inhibit cardiomyocyte death. In a doxorubicin-induced mouse model of dilated cardiomyopathy (DCM), intravenous infusion of canine CDCs improves cardiac function and decreases cardiac fibrosis. Histology revealed that injected canine CDCs engraft in the mouse heart and increase capillary density. Out study demonstrates the regenerative potential of canine CDCs in a mouse model of DCM.


Subject(s)
Heart/physiology , Myocytes, Cardiac/cytology , Regeneration , Spheroids, Cellular/cytology , Aging , Animals , Apoptosis , Cell Differentiation , Cells, Cultured , Dogs , Female , Fibrosis , Heart Function Tests , Mice, SCID , Myocardium/pathology , Neovascularization, Physiologic , Paracrine Communication
SELECTION OF CITATIONS
SEARCH DETAIL
...